GZMB Recombinant Monoclonal Antibody

Code: CSB-RA010082MA1HU

Rate （N/A）
Review （0）

Size:

50μl100μl

US$210

Quantity:

Species Reactivity: Human

Application: ELISA, WB, IHC, FC

Send an Inquiry

Start an on-line Chat

Online ordering is currently available for U.S. customers only. For orders outside the U.S., please kindly submit an inquiry or start a chat with us.

Product Details
Related Products
Customer Reviews and Q&A
Target Background

Product Details

Uniprot NO.

P10144

Target Names

GZMB

Alternative Names

C11 antibody; Cathepsin G like 1 antibody; Cathepsin G-like 1 antibody; CCPI antibody; CGL 1 antibody; CGL1 antibody; CSP B antibody; CSPB antibody; CTLA 1 antibody; CTLA-1 antibody; CTLA1 antibody; CTSGL1 antibody; Cytotoxic serine protease B antibody; Cytotoxic T lymphocyte associated serine esterase 1 antibody; Cytotoxic T lymphocyte proteinase 2 antibody; Cytotoxic T-lymphocyte proteinase 2 antibody; Fragmentin 2 antibody; Fragmentin-2 antibody; GRAB_HUMAN antibody; Granzyme 2 antibody; Granzyme B (granzyme 2; cytotoxic T lymphocyte associated serine esterase 1) antibody; Granzyme B antibody; Granzyme-2 antibody; GranzymeB antibody; GRB antibody; Gzmb antibody; Hlp antibody; Human lymphocyte protein antibody; Lymphocyte protease antibody; Protease; serine; B antibody; SECT antibody; T cell serine protease 1 3E antibody; T cell serine protease 1-3E antibody; T-cell serine protease 1-3E antibody

Species Reactivity

Human

Immunogen

Recombinant Human GZMB protein

Conjugate

Non-conjugated

Clonality

Monoclonal

Isotype

mIgG2a

Clone No.

9B2

Purification Method

Affinity-chromatography

Concentration

It differs from different batches. Please contact us to confirm it.

Buffer

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4

Form

Liquid
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.

Scope Application

ELISA Protocol Western Blotting(WB) Protocol Immunohistochemistry (IHC) Protocol Flow Cytometry (FC) Protocol

Recommended Dilution

Application	Recommended Dilution
WB	1:500-1:2000
IHC	1:50-1:200
FC	1:50-1:200

Storage

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Lead Time

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Note: All of our proteins are default shipped with normal blue ice packs, if you request to ship with dry ice, please communicate with us in advance and extra fees will be charged.

Usage

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Datasheet & COA

Antibody FAQs

Images

Western Blot Positive WB detected in:K562 whole cell lysate (20µg) All lanes: GZMB antibody at 1:1000 Secondary Goat polyclonal to mouse IgG at 1/50000 dilution Predicted band size:27.7 kDa Observed band size:28 kDa Exposure time:300s
IHC image of CSB-RA010082MA1HU diluted at 1:50 and staining in paraffin-embedded human tonsil tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a Goat anti-Mouse IgG labeled by HRP and visualized using 0.05% DAB.
Overlay Peak curve showing THP-1 cells stained with CSB-RA010082MA1HU (red line) at 1:50. The cells were fixed in 4% formaldehyde and permeated by 0.2% TritonX-100. Then 10% normal goat serum to block non-specific protein-protein interactions followed by the antibody (1ug/1*10⁶cells) for 45min at 4℃. The secondary antibody used was FITC-conjugated Goat Anti-Mouse IgG(H+L) at 1:200 dilution for 35min at 4℃.Control antibody (green line) was mouse IgG (1ug/1*10⁶cells) used under the same conditions. Acquisition of >10,000 events was performed.

Description

Granzyme B is a serine protease that plays a central role in immune-mediated cell death, functioning as a key effector molecule released by cytotoxic T lymphocytes and natural killer cells. Upon delivery into target cells, this enzyme initiates apoptosis through both caspase-dependent and caspase-independent pathways, making it an essential marker for studying cytotoxic immune responses, tumor immunology, and inflammatory conditions.

This recombinant monoclonal antibody against human Granzyme B offers the consistency and reliability that demanding experimental workflows require. Produced using recombinant technology with a defined sequence, this antibody eliminates the lot-to-lot variability often encountered with traditional hybridoma-derived reagents, ensuring reproducible results across extended studies and multi-site collaborations.

Validation across multiple platforms demonstrates the versatility of this antibody for diverse experimental approaches. Western blot analysis of K562 whole cell lysate reveals a clean band at approximately 28 kDa, closely matching the predicted molecular weight of 27.7 kDa and confirming specific target recognition. Immunohistochemical staining in paraffin-embedded human tonsil tissue shows clear detection of Granzyme B-positive cells, providing researchers with a reliable tool for examining cytotoxic cell infiltration in tissue sections. Flow cytometry analysis using THP-1 cells demonstrates distinct positive signal separation from isotype controls, enabling quantitative assessment of intracellular Granzyme B expression in cell populations.

Whether investigating tumor-infiltrating lymphocyte activity, characterizing immune cell phenotypes, or examining cytotoxic mechanisms in disease models, this antibody provides the specificity and application flexibility needed for immunology and cell biology research focused on understanding immune effector function.

Customer Reviews and Q&A

■ Customer Reviews

Submit a Review here

Target Background

Function(From Uniprot)

Abundant protease in the cytosolic granules of cytotoxic T-cells and NK-cells which activates caspase-independent pyroptosis when delivered into the target cell through the immunological synapse. It cleaves after Asp. Once delivered into the target cell, acts by catalyzing cleavage of gasdermin-E (GSDME), releasing the pore-forming moiety of GSDME, thereby triggering pyroptosis and target cell death. Seems to be linked to an activation cascade of caspases (aspartate-specific cysteine proteases) responsible for apoptosis execution. Cleaves caspase-3, -7, -9 and 10 to give rise to active enzymes mediating apoptosis.

Gene References into Functions

our exploratory study suggests that EOMES, BCL6 and GZMB gene expression are aberrant within the PB T cell transcriptome of HT patients. The association of this transcription signature with the heterogeneity of HT and disease control is suggested. PMID:29319368
Serum interleukin 1 receptor antagonist (IL1RA) and granzyme B (GZMB) levels were markedly increased in Crohn's disease (CD) patients, suggesting that these markers can serve as biomarkers to identify gut inflammation. PMID:28972805
Authors found that R(48)-GzmB is a stable protein that accumulates to similar levels in activated NK cells as Q(48)-GzmB. rs8192917 polymorphism may influence antitumor activity and the effect of antitumor cellular immunotherapy. PMID:28653095
GzmA and gzmB were predominantly expressed by natural killer cells, and during abdominal sepsis, the percentage of these cells expressing gzms in peritoneal lavage fluid decreased, while the amount of expression in the gzm(+) cells increased PMID:28694562
Study provides evidence that Il10 expression is limited to migratory CD25++ regulatory T cells only. PMID:27756896
Long-term lung function decline in asthma is associated with elevation of bronchial CD8 and CD4 at baseline, and CD8, CD3 and granzyme B at follow-up PMID:27230446
Granzyme B breaches the inner membrane through Tim22, the metabolite carrier translocase pore, in a mitochondrial heat-shock protein 70-dependent manner. PMID:28338658
Differential proteomics were used to identify granzyme B substrates in three unrelated bacteria: Escherichia coli, Listeria monocytogenes, and Mycobacteria tuberculosis. Granzyme B cleaves a highly conserved set of proteins in all three bacteria, which function in vital biosynthetic and metabolic pathways that are critical for bacterial survival under diverse environmental conditions. PMID:29107333
Proteolysis by granzyme B enhances presentation of autoantigenic PAD4 epitopes in rheumatoid arthritis. PMID:27700100
our results suggest granzyme B PET imaging can serve as a quantitatively useful predictive biomarker for efficacious responses to cancer immunotherapy. PMID:28461564
Plasma GzmB levels may reflect the degree of pruritus and dermatitis in patients with atopic dermatitis PMID:27686401
These results suggest the critical importance of miR-378 in the regulation of GrzB expression and a protective role for GrzB in controlling dengue virus replication in vivo. PMID:26166761
Analysis of infiltrating granzyme B-expressing T cells at the invasive borders of the colon tumors revealed a significant difference in expression granzyme by race underlining decreased antitumor cytotoxic immunity in African Americans. PMID:27310868
Increased TIM3+CD8+T cells with lower perforin and granzyme B expression and higher CD95 expression in MDS patients were observed. PMID:27846431
granzyme-B levels were found to be significantly associated with increased insulin resistance in adolescent polycystic ovary syndrome patients. Additionally, elevated levels of serum granzyme-B were predictive for increased cardiovascular risk in PCOS patients PMID:26802256
results suggest that enhanced IL-21R expression of CD19(+)CD5(+) B cells and production of IL-21 by iNKT cells may play an important role in the pathogenesis of pSS by regulating CD19(+)CD5(+) B cell functions and increasing GrB production, presumably leading to a counter-regulatory effect in the disease. PMID:26884645
Findings show that GrB was produced in 57.1% colorectal cancer cell (CRC) lines and 100% CRC-derived Cancer Stem Cells and present a novel role for GrB as up-modulator of epitelial-to-mesenchimal transition in CRC cells. PMID:26830472
FASL, granzyme B, and cytochrome c blood expression reflects breast cancer progression and response to therapy. (Review) PMID:27117663
Data show that NK cell lines could secreted rapidly inactive Mr 35 000 granzyme B (GZB)outside secretory lysosomes (SLs). PMID:26927382
Data suggest that reactive oxygen species (ROS) generated within cytotoxic lymphocytes by receptor stimulation are required for lysosomal permeabilization and release of GzmB (granzyme B) into the cytosol and for inactivation of serpin B9. PMID:26670609
these results suggest a perforin-independent, extracellular role for GzmB in the pathogenesis of cardiac fibrosis PMID:26610869
Among SLAMF4+ cells, the T cell fraction positive for perforin and granzyme B was higher in those obtained from healthy donors, while the percentage of T cells that were single-positive for granzyme B was higher in cells obtained from patients with SLE. PMID:26314831
Costimulation blockade by abatacept can decrease the serum levels of GZMB in rheumatoid arthritis patients responding to the treatment. PMID:26633185
elevated in the inflammatory lesions of placentas with villitis of unknown etiology PMID:25725937
Combined evaluation of granzyme B and perforin may have a role in noninvasive diagnosis of acute rejection after kidney transplantation. PMID:25643139
this study emphasizes that the coordinated action of hGzmB-activated p53 and GzmB-cleaved Bid is important for GzmB-induced cell death and for cytotoxic lymphocyte/Natural Killer Cell-mediated killing of target cells. PMID:25404359
identified among the key genes in circulating monocytes that were altered by exercise PMID:26207425
GB-induced ROS significantly promote apoptosis. PMID:25361078
Active secretion of CXCL10 and CCL5 from colorectal cancer microenvironments associates with granzymeB+ CD8+ T-cell infiltration. PMID:25671296
Synthetic consensus HIV-1 DNA induces potent cellular immune responses and synthesis of granzyme B, perforin in HIV infected individuals. PMID:25531694
GzmB plays no role in the pathogenesis of keloids and hypertrophic scars. PMID:26410968
PFN appears to form arc structures on target membranes that serve as minimally disrupting conduits for GzmB translocation. PMID:25146929
These results suggest that GZMB Q55R, P94A, and Y247H polymorphisms are not significantly associated with colon cancer incidence, or metastasis to lymph node and distant organ. PMID:25313744
CD4+ T cell-derived IL-21 and deprivation of CD40 signaling favor the in vivo development of granzyme B-expressing regulatory B cells in HIV patients. PMID:25780036
Data indicate that treatment with toll-like receptor 8 (TLR8) agonists elicited granzyme B production. PMID:25667415
The results of study found implicate possible effect of this genetic polymorphism in susceptibility to SSPE which needs to be confirmed in bigger populations. PMID:24875585
Activated CD4 and CD8 T cells secrete similar amounts of GrzB. PMID:25245659
The suppression-abrogating cytokine IL-6 augments GzmB expression by human CD4 T cells, and it inhibits Treg suppression via a nonapoptotic GzmB-mediated mechanism. PMID:25637022
Polarized granzyme release is required for antigen-driven transendothelial migration of human effector memory CD4 T cells. PMID:25367116
CASP is specifically cleaved by granzymeB. PMID:25159843
Serum concentrations of granzyme B in patients with ovarian cancer were substantially increased in comparison to concentrations in patients with ovarian cystadenomas or ovarian teratomas. PMID:24673566
The GrB-Sb9 nexus may therefore represent an additional mechanism of limiting lymphocyte lifespan and populations. PMID:24488096
our data indicate that the co-expression of perforin and granzyme B genes exhibits anticancer potential PMID:24696715
Cancer cells released soluble factors that inhibited granzyme B, perforin and IFN-gamma production. PMID:24894428
multiple linear regression analysis revealed that both type 2 diabetes mellitus and central obesity were predicting factors for GzmB, findings reveal a possible role of GzmB in type 2 diabetes mellitus. PMID:24195710
cleaves proIL-18 into active form and promotes apoptosis in the inflammed skin PMID:23820889
These results suggest that GrzB from CCR5+ memory CD4 T cells may have a role in cellular and tissue pathologies during HIV infection. PMID:24999042
These data indicate that IBD-related inflammation is marked by mucosal accumulation of cytotoxic, GrB-expressing CD19(+) and IgA(+) cells, suggesting a role for these cells in IBD-associated epithelial damage. PMID:24835396
Report increased granzyme B expression in discoid lupus erythematosus. PMID:23980805
Unlike IL-18 and FKN, plasma GZB may have a role in severity of acute coronary syndrome PMID:24307760